Kairos Pharma, LTD. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kairos Pharma, LTD. (KAPA) on July 22, 2026, covering events occurring on July 16, 2026. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Los Angeles, CA. The filing primarily addresses the entry into a material definitive agreement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a strategic partnership rather than periodic financial performance data.
Material Changes and Agreements
On July 16, 2026, the Company entered into an Agreement for the Support of Investigator/Institution Initiated Research (IIR Agreement) with Bayer HealthCare Pharmaceuticals Inc. Key terms include:
- Collaboration Scope: Bayer will provide radium for a study investigating the therapeutic activity of radium combined with ENV-105 (carotuximab) in models of prostate cancer bone metastasis.
- Company Obligations: Kairos Pharma is solely responsible for initiating, managing, and financing the Study. The Company must provide final analysis, interpretation, and conclusions to Bayer within 6 months of the Study's completion.
- Control Provisions: The Company must obtain prior written approval from Bayer before making any material changes to Study protocols.
- Covenants: The agreement includes standard provisions regarding compliance with laws, insurance, indemnification, confidentiality, publication, liability, and remedies.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary regarding future earnings. The primary risk and contingency noted is the requirement for Bayer's prior written approval for any material changes to the Study protocols, which may impact the Company's operational flexibility regarding the research.
Investor Verification Checklist
- Verify the specific terms of the IIR Agreement filed as Exhibit 10.1, noting that certain confidential information has been redacted.
- Confirm the Company's current cash position and ability to finance the Study independently, as required by the agreement.
- Review the press release (Exhibit 99.1) for additional context on the strategic importance of the radium and ENV-105 combination.
- Monitor future filings for the Study's completion date and the subsequent delivery of analysis to Bayer.